ArticlePakistan journal of medical sciences
Changes of plasma aldosterone and angiotensin II levels in patients with ischemic cardiomyopathy combined with Type-2 diabetes mellitus and their clinical significance.
Article in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the changes of plasma aldosterone (ALD) and angiotensin II (Ang II) levels in patients with ischemic cardiomyopathy (ICM) combined with Type-2 diabetes mellitus (T2DM) and their clinical significance. Methods: Sixty-eight patients with ICM combined with T2DM and fifty-two patients with simple ICM treated in the People's Hospital of Three Gorges University/the First People's Hospital of Yichang from February 2018 to February 2021 were selected as observation group and control group, respectively. All the patients had intervention with the same neuroendocrine hormone regime. The plasma ALD and Ang II and left ventricular function indexes (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD)] were measured and compared between the two groups before and after treatment. The correlations of plasma ALD and Ang-II with left ventricular function before treatment were analyzed using Pearson's correlation analysis. The diagnostic efficacy of plasma ALD and Ang-II in ICM and T2DM was evaluated by the receiver operating characteristic (ROC) curve. Results: Before treatment, the plasma ALD and Ang II levels in the observation group were (184.42 ± 56.75) ng/L and (46.68 ± 12.16) ng/L, respectively, which were significantly higher than those in the control group [(165.03 ± 45.67) ng/L and (39.70 ± 10.69) ng/L, p< 0.05]. Compared with before treatment, ALD level increased significantly in the observation group while decreased significantly in the control group after treatment ( Conclusion: The plasma levels of ALD and Ang-II in patients with ICM combined with T2DM increase significantly, and their diagnostic value is not high. Compared with patients with simple ICM, the decrease in plasma ALD and Ang- II levels is less obvious after the same intervention, but it is still conducive to the improvement of cardiac function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.